Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Around 40% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure. Chemotherapy, such as docetaxel (DTX), can enhance the efficacy of RT. Multidrug resistance mechanisms often limit drug efficacy by decreasing intracellular concentrations of drugs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mirjolet, Céline, Boudon, Julien, Loiseau, Alexis, Chevrier, Sandy, Boidot, Romain, Oudot, Alexandra, Collin, Bertrand, Martin, Etienne, Joy, Pattayil Alias, Millot, Nadine, Créhange, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587207/
https://www.ncbi.nlm.nih.gov/pubmed/28919739
http://dx.doi.org/10.2147/IJN.S139167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587207/
https://www.ncbi.nlm.nih.gov/pubmed/28919739
http://dx.doi.org/10.2147/IJN.S139167

Ejemplares similares